Clinical trials
Recurrent Head and Neck Cancer clinical trials
Below are recruiting recurrent head and neck cancer clinical trials, each written for real people, not researchers. We’re tracking 213 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03145077Recruiting
MRI test to diagnose jaw bone damage after head and neck radiation
This study uses special MRI scans with contrast to better detect osteoradionecrosis (jaw bone injury) after radiation for head and neck cancer. If you qualify, the scans may help your team diagnose problems earlier and choose the right next treatment.
Houston, TexasAges 18 years+ - NCT03238378Recruiting
Radiation boost plus warming for recurrent head and neck tumors
This trial tests a “salvage” treatment that combines targeted radiation (brachytherapy) with controlled body warming (hyperthermia) for head and neck cancer that has come back. It may help by better shrinking tumors while fitting the treatment to the tumor’s exact location.
ErlangenAges 18 years+ - NCT03481647Recruiting
Oral care program for people getting head and neck radiation
This trial tests an oral (mouth) care program for people with head and neck cancer who are about to start full-dose, curative radiation. It may help protect your mouth and salivary glands during treatment.
GothenburgAges 18–80 - NCT03483337Recruiting
MRI scan tests new markers for head and neck cancers
This trial tests special MRI scans to find warning signs of cancer that has returned or spread in the head and neck area. It may help doctors see these changes more clearly, which could improve treatment planning.
New York, New YorkAges 18 years+ - NCT04375384RecruitingPhase 2
Cetuximab after immunotherapy for head and neck cancer
This trial studies whether giving cetuximab after prior immunotherapy can help people with head and neck squamous cell cancer shrink tumors or slow their growth. You may be eligible if you’ve already had a PD-1–based immunotherapy treatment, and you meet health and safety requirements.
Winston-Salem, North CarolinaAges 18 years+ - NCT04429542RecruitingPhase 1
Test of an EGFR-targeting drug for advanced solid cancers
This Phase 1 study tests the safety of BCA101 (an EGFR-targeting treatment) alone or combined with pembrolizumab. It may help people with certain EGFR-driven advanced cancers, depending on the tumor type, prior treatments, and required biopsy testing.
La Jolla, CaliforniaAges 18 years+ - NCT04511078RecruitingPhase 2
Panitumumab-IRDye800 during head and neck surgery
This Phase 2 study tests a targeted medicine (panitumumab-IRDye800) given around the time of surgery for head and neck squamous cell cancer. It aims to improve doctors’ ability to find and remove cancer tissue during planned surgery.
Birmingham, AlabamaAges 18 years+ - NCT04534205RecruitingPhase 2/Phase 3
Testing BNT113 plus pembrolizumab versus pembrolizumab alone
This trial studies whether adding BNT113 to pembrolizumab works better and is safe for people with HPV16-positive head and neck cancer that can’t be cured with local treatments. It also compares outcomes to pembrolizumab alone, specifically for tumors that show PD-L1 in testing.
Los Angeles, CaliforniaAges 18 years+ - NCT04545957Recruiting
Radiation planning study using MRI for adults with cancer
This trial tests a “master protocol” approach to use MRI (a detailed body scan) to help plan radiation treatment for people with cancer. It may help doctors customize radiation more accurately, depending on your specific cancer type.
Boston, MassachusettsAges 18 years+ - NCT04671667RecruitingPhase 2
Pembrolizumab vs chemo-radiation after surgery for recurrent head/neck cancer
This trial tests whether pembrolizumab (an immunotherapy drug) works better than the usual chemo plus radiation after surgery for cancer that has come back in the head and neck area. It may help reduce cancer returning or spreading by using your immune system, but eligibility depends on how the cancer came back and your prior treatments.
Birmingham, AlabamaAges 18–79 - NCT04868162RecruitingPhase 2
MRG003 for head and neck cancer after prior treatments
This trial tests MRG003, a cancer medicine, in people with recurrent or metastatic squamous cell carcinoma of the head and neck who have already tried and had trouble with standard treatments like platinum and anti–PD-1 therapy. It looks at whether the treatment can shrink the cancer and how safe it is.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04930432RecruitingPhase 1/Phase 2
MCLA-129 for advanced EGFR- and MET-positive lung and other cancers
This early-phase trial tests MCLA-129, an antibody that targets EGFR and MET, in people with advanced cancers that have specific lab “biomarker” results. It’s for patients whose cancer has grown after standard treatments or can’t take standard treatment, with the goal of shrinking tumors and improving symptoms.
BaodingAges 18 years+ - NCT05005403RecruitingPhase 1
Testing azirkitug for lung, head/neck, and other solid cancers
This Phase 1 study tests how a new medicine (azirkitug) behaves in the body and how safe it is, given by IV infusion alone or with other cancer drugs. It may help people with several advanced solid tumor cancers, especially after standard treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT05047094Recruiting
DaRT radiation plus pembrolizumab for head and neck cancer
This trial tests whether a targeted internal radiation treatment (DaRT) combined with pembrolizumab (an immune therapy) can shrink recurrent or metastatic head and neck squamous cell cancer that cannot be fully removed with surgery. It may help by making cancer more visible to the immune system while delivering localized radiation to a tumor area.
JerusalemAges 18 years+ - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Duarte, CaliforniaAges 18 years+ - NCT05144698RecruitingPhase 1/Phase 2
RAPA-201 cell therapy for certain advanced lung and head cancers
This Phase 1/2 trial tests RAPA-201, a personalized immune cell treatment made from your own T cells, for advanced solid tumors. It may help people whose cancer has come back after standard treatment and after an anti–PD-1/PD-L1 antibody.
Hackensack, New JerseyAges 18 years+ - NCT05207098Recruiting
Brain testing and questionnaires during head and neck radiation
This study checks how people’s thinking and brain functioning change while they are getting radiation therapy for head and neck cancer. It uses simple computer tests and questionnaires to better understand who may be at risk for trouble thinking during treatment.
Basking Ridge, New JerseyAges 18–89 - NCT05231655Recruiting
Study testing fresh tumor tissue from cancer surgery or biopsy
This study collects fresh samples of tumor tissue during procedures like surgery, biopsy, or TURBT to test a cancer therapy outside the body. It may help researchers learn which treatments work better for different solid cancers.
Sheffield, South YorkshireAges 16 years+ - NCT05260671RecruitingPhase 2
Penpulimab plus cetuximab for advanced head and neck cancer
This trial studies penpulimab (an immune medicine) combined with cetuximab (an antibody drug) for recurrent or metastatic squamous cell head and neck cancer that cannot be treated with surgery or radiation. It aims to shrink tumors and improve survival in people whose tumor shows a specific immune marker (PD-L1).
Changchun, JilinAges 18–80 - NCT05283226RecruitingPhase 2
Oral anti-cancer pill plus paclitaxel after immunotherapy failure
This Phase 2 trial studies an oral study drug (NRC-2694-A) given with paclitaxel to treat head and neck squamous cell cancer that has come back or spread after immunotherapy. It tests whether this combination is safer and works better than expected for people whose cancer progressed on immune checkpoint inhibitors.
Fullerton, CaliforniaAges 18 years+ - NCT05328024Recruiting
Testing who benefits from anti–PD-1 immunotherapy in head cancer
This study looks for signs in your tumor that can predict how well anti–PD-1 immunotherapy will work for certain head and neck cancers. You may benefit by helping doctors match the right treatment to the right patients.
Strasbourg, FranceAges 18 years+ - NCT05366881Recruiting
Blood test study to spot early cancer signal and cancer leftovers
This observational study checks whether a blood test (a “cfDNA” test) can detect early signs of cancer or small amounts of cancer left after treatment. It may help doctors use a simple blood sample to improve cancer detection and follow-up.
Duarte, CaliforniaAges 40 years+ - NCT05420948RecruitingPhase 2
Pembrolizumab with chemotherapy for returning or spread head cancer
This Phase 2 study tests pembrolizumab (an immunotherapy) plus chemotherapy to treat head and neck cancer that has come back or spread. You might be eligible if standard local treatments won’t be curative and your tumor can be measured on scans.
Chicago, IllinoisAges 18 years+ - NCT05483374Recruiting
Head and neck cancer registry for adult patients
This study builds a European database (registry) of adults with certain head and neck cancers to better understand how these cancers are diagnosed and treated over time. It may help future care by collecting real-world information, rather than testing a new medicine.
Brno, BrnoAges 18 years+
Hear when a new Recurrent Head and Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent head and neck cancer?
- Yes. Clin2 currently lists 213 recruiting recurrent head and neck cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent head and neck cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent head and neck cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Head and Neck Cancer
- Recurrent Head and Neck Squamous Cell Carcinoma
- Head and Neck Squamous Cell Cancer
- Head and Neck Cancer (H&N)
- Head and Neck Cancer Squamous Cell Carcinoma
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
- Head &Amp; Neck Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.